Refine
Has Fulltext
- yes (9)
Is part of the Bibliography
- yes (9)
Document Type
- Journal article (9)
Language
- English (9)
Keywords
- CXCR4 (7)
- chemokine receptor (3)
- molecular imaging (3)
- PET (2)
- PET/CT (2)
- Pentixafor (2)
- multiple myeloma (2)
- positron emission tomography (2)
- solid tumors (2)
- theranostics (2)
Institute
- Klinik und Poliklinik für Nuklearmedizin (9)
- Pathologisches Institut (6)
- Medizinische Klinik und Poliklinik II (2)
- Neurochirurgische Klinik und Poliklinik (2)
- Abteilung für Molekulare Innere Medizin (in der Medizinischen Klinik und Poliklinik II) (1)
- Deutsches Zentrum für Herzinsuffizienz (DZHI) (1)
- Medizinische Klinik und Poliklinik I (1)
EU-Project number / Contract (GA) number
- 701983 (1)
Despite improved survival in the Rituximab (R) era, a considerable number of patients with diffuse large B-cell lymphoma (DLBCL) ultimately die from the disease. Functional imaging using [18F]fluorodeoxyglucose-PET is suggested for assessment of residual viable tumor very early during treatment but is compromised by non-specific tracer retention in inflammatory lesions. The PET tracer [18F]fluorodeoxythymidine (FLT) as surrogate marker of tumor proliferation may overcome this limitation. We present results of a prospective clinical study testing FLT-PET as superior and early predictor of response to chemotherapy and outcome in DLBCL. 54 patients underwent FLT-PET prior to and one week after the start of R-CHOP chemotherapy. Repetitive FLT-PET imaging was readily implemented into the diagnostic work-up. Our data demonstrate that the reduction of FLT standard uptake valuemean (SUVmean) and SUVmax one week after chemotherapy was significantly higher in patients achieving complete response (CR, n=48; non-CR, n=6; p<0.006). Martingale-residual and Cox proportional hazard analyses showed a significant monotonous decrease of mortality risk with increasing change in SUV. Consistent with these results, early FLT-PET response showed relevant discriminative ability in predicting CR. In conclusion, very early FLT-PET in the course of R-CHOP chemotherapy is feasible and enables identification of patients at risk for treatment failure.